Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  PPD, Inc.    PPD

PPD, INC.

(PPD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

PPD : Announces Third Quarter 2020 Earnings Conference Call

10/12/2020 | 04:07pm EST

PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, will host a conference call on Wednesday, Oct. 28, 2020, at 9 a.m. (U.S. Eastern Time) to discuss its third quarter 2020 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging onto the investors section of PPD’s website at https://investors.ppd.com. An archive copy of the webcast will be available on the website after the call.

In addition, the conference call can be accessed live over the phone by dialing +1 877 407 0784, or for international callers, +1 201 689 8560. A replay will be available after the call and can be accessed by dialing +1 844 512 2921, or for international callers, +1 412 317 6671. The passcode for the live conference call and the replay is 13711906. The audio replay will be available until Wednesday, Nov. 11, 2020.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 25,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppd.com.


© Business Wire 2020
All news about PPD, INC.
01/14PPD, INC. : Entry into a Material Definitive Agreement, Termination of a Materia..
AQ
01/11PPD, INC. : Regulation FD Disclosure (form 8-K)
AQ
01/11EQS-NEWS : Relief, NeuroRx and Quantum Leap announce the inclusion of ZYESAMI(TM..
DJ
01/06DAI ICHI KARKARIA : Gets Closure Order for Unit from Gujarat Pollution Control B..
MT
01/04PPD : to Present at the 39th Annual J.P. Morgan Healthcare Conference
BU
2020MODERNA : Announces FDA Authorization of Moderna COVID-19 Vaccine in U.S.
AQ
2020PPD, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2020PPD : Recognized as a Best Place to Work in Greater China
BU
2020EQS-NEWS : Relief Therapeutics and NeuroRx Meet 165 Patient Enrollment Target in..
DJ
2020MARKET CHATTER : US Clears New Drug Application for LG Chem’s Liver Diseas..
MT
More news
Financials (USD)
Sales 2020 4 586 M - -
Net income 2020 140 M - -
Net Debt 2020 3 428 M - -
P/E ratio 2020 89,3x
Yield 2020 -
Capitalization 12 539 M 12 539 M -
EV / Sales 2020 3,48x
EV / Sales 2021 3,06x
Nbr of Employees 23 000
Free-Float 61,2%
Chart PPD, INC.
Duration : Period :
PPD, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PPD, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Average target price 39,50 $
Last Close Price 35,86 $
Spread / Highest target 19,9%
Spread / Average Target 10,2%
Spread / Lowest Target -12,2%
EPS Revisions
Managers and Directors
NameTitle
David S. Simmons Chairman & Chief Executive Officer
William Jacob Sharbaugh Chief Operating Officer
Christopher G. Scully CFO, Treasurer, Executive VP & Assistant Secretary
David Johnston Executive VP-Global Clinical Development
Karen Kaucic Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PPD, INC.4.79%12 539
MODERNA, INC.19.79%49 468
LONZA GROUP AG1.97%48 472
CELLTRION, INC.-13.37%38 667
IQVIA HOLDINGS INC.6.35%36 230
SEAGEN INC.8.94%34 149